Risk factors for revictimization during treatment in patients with co-occurring SUD and PTSD.

Eur J PsychotraumatolFeb 3, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Nathalie N M Faber, Christin Kühner, Carolien Christ et al.

✦ AI-curated · Sources linked

In 30 seconds

This analysis of the Treatment of PTSD and Addiction randomized controlled trial examined factors associated with revictimization among 203 patients with co-occurring substance use disorder and post-traumatic stress disorder who had experienced interpersonal victimization at baseline. Over 9 months, 42.5% experienced revictimization. Physical violence was the most common reported type (26.0%), followed by other unwanted sexual experiences (20.0%). PTSD severity and age were univariate predictors, but only age remained robustly associated after accounting for the other study variables; younger age was associated with greater risk.

Key findings

  • Revictimization occurred in 42.5% of participants during the 9-month follow-up.
  • Physical violence was reported by 26.0%, and other unwanted sexual experiences by 20.0%.
  • PTSD severity and age were univariate predictors, but only younger age remained robustly associated with revictimization after adjustment.

Why it matters

The findings indicate that repeated interpersonal victimization is a substantial concern among patients receiving treatment for co-occurring SUD and PTSD. Recognising this burden can support clinical attention to patients’ safety and inform research into factors linked to vulnerability, while the observed age association does not establish a causal mechanism.

What to keep in mind

The analysis included only patients with interpersonal victimization at baseline, and follow-up was limited to 9 months. The reported associations do not establish causation.

Source

Published in Eur J Psychotraumatol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.